The Chordoma Foundation (CF) and The Mark Foundation for Cancer Research (MFCR) announced today a two-year, $1.4M partnership with a team of researchers at three institutions to develop new treatments for chordoma, a rare and difficult-to-treat bone cancer. The researchers will focus on creating the first drugs to inhibit a protein known as brachyury. Continue reading

We’re excited to announce that the Chordoma Foundation and the Broad Institute of Harvard and MIT recently embarked upon the most thorough effort yet to identify existing drugs with the potential to provide new treatments for chordoma patients. Continue reading

Originally published on the Cancer Research Institute blog.   By Arthur N. Brodsky, PhD Sarcomas are an aggressive type of … Continue reading

The Cancer Research Institute (CRI) and Chordoma Foundation announced today that they have established a research partnership to advance treatment … Continue reading

I’m excited to share the findings of a new paper published earlier this week in the journal Nature Medicine that … Continue reading

At the end of 2018, the Chordoma Foundation and the Canadian Cancer Society (CCS) together awarded two new grants totaling … Continue reading